LCC is an international, chemistry-based CRO on a mission to accelerate your discovery. Its technologies unlock thousands of functionalised (chiral) building blocks that cover some of the gaps in existing 3D chemical space through a combination of novel scaffolds and novel variants of privileged scaffolds.
LCC’s products are categorised to serve specific hit-identification screening technologies, including:
(a) monomers and scaffolds for DEL synthesis,
(b) collections of fragments for FBLD (including covalent, fluoro derivatives and enantioprobes),
(c) semi-flexible linkers for PROTACs,
(d) chiral API and intermediates for 'Me-Too' drug discovery.
With a variety of core technologies and strengths, and facilities that allow production from mg to multi-kg scale, LCC's product pipeline is continuously evolving. Through an ethos of purposeful curiosity, LCC’s goal is to help the development of high-quality drugs, in order to bring new drugs to market faster, better and easier.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner